Communicators

are winners!

More News

04.03.2024
BioNxt Reports Completion of ODF Cladribine PK Study
08.02.2024
BioNxt Reports Successful Results From ODF Cladribine Toxicity Study
22.12.2023
BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
12.12.2023
BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
20.11.2023
BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treatment
15.11.2023
BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
13.11.2023
BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
06.11.2023
BioNxt Solutions Reports on Barcelona CPHI Conference
02.08.2023
BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease
15.05.2023
BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson’s Disease